CD97 Antibody

What are the optimal applications for different types of CD97 antibodies?

Different CD97 antibodies have specific applications where they perform optimally:

• Monoclonal antibodies (like MAB2529) are excellent for flow cytometry and direct ELISAs, detecting human CD97 with high specificity . They show minimal cross-reactivity with mouse CD97 in Western blots.

• Polyclonal antibodies (like 13071-1-AP) offer broader epitope recognition and are suitable for Western blot (1:500-1:1000 dilution) and immunohistochemistry (1:50-1:500 dilution) .

• Mouse monoclonal antibodies (like 66972-1-Ig) work well for both Western blot (1:1000-1:4000) and immunofluorescence (1:400-1:1600) applications .

Application selection should be based on the specific research question and sample type, as each antibody shows different performance characteristics across applications.

What are the recommended sample preparation methods for detecting CD97 in different cell types?

Sample preparation should be optimized based on cell type and application:

For human blood samples:

• In flow cytometry applications, whole blood samples should be processed with minimal manipulation to preserve surface epitopes .

• Red blood cell lysis buffers should be used carefully to avoid affecting CD97 expression.

For cell lines in Western blot:

• Effective detection has been validated in multiple cell types including HepG2, K-562, U-937, and Jurkat cells .

• Complete cell lysis buffers containing protease inhibitors are recommended to capture the full 75-85 kDa protein.

For tissue samples in IHC:

• Antigen retrieval with TE buffer pH 9.0 is suggested for optimal staining of human tonsillitis and lymphoma tissues .

• Alternatively, citrate buffer pH 6.0 can be used, but may yield different staining intensities.

How can I optimize CD97 antibody dilution for different experimental conditions?

Antibody dilution optimization requires systematic titration based on:

• Application-specific starting points:

  • Western blot: Begin with manufacturer recommendations (e.g., 1:500-1:1000 for polyclonal or 1:1000-1:4000 for monoclonal )

  • IHC: Start with 1:50-1:500 dilution

  • IF/ICC: Begin with 1:400-1:1600 dilution

  • Flow cytometry: Follow manufacturer protocols, typically higher concentrations

• Sample-dependent considerations:

  • Higher antibody concentrations may be needed for samples with lower CD97 expression

  • Cell lines with high CD97 expression (e.g., GSCs) may require more dilute antibody solutions

• Methodological approach:

  • Perform a dilution series (e.g., 2-fold dilutions)

  • Include positive controls (validated CD97-expressing cells like K-562)

  • Include negative controls (isotype controls, e.g., MAB0031 for flow cytometry)

  • Evaluate signal-to-noise ratio to determine optimal concentration

How can CD97 antibodies be utilized to investigate the role of CD97 in glioblastoma stem cells (GSCs)?

CD97 antibodies are powerful tools for GSC research based on recent findings that CD97 is a GSC-enriched surface antigen:

Flow cytometry applications:

• CD97 antibodies can isolate CD97^high and CD97^-/low populations from GSCs for comparative studies .

• Researchers can establish CD97 as a surface marker by correlating its expression with established GSC markers (Nestin, Oct3/4, and Nanog) .

Co-localization studies:

• Immunofluorescence using CD97 antibodies alongside GSC markers (Nestin) in xenograft tissues can validate spatial relationships .

• For optimal results, use tissue fixation protocols that preserve cell surface epitopes.

Functional studies:

• After CD97^high cell isolation, antibodies can be used to monitor changes in CD97 levels during:

  • Self-renewal experiments

  • Proliferation assays

  • Differentiation protocols

  • Tumorigenicity assessments

Methodological procedure:

• Establish primary GSC cultures from patient samples

• Validate CD97 expression using flow cytometry with appropriate controls

• Sort CD97^high and CD97^-/low populations

• Verify enrichment using qPCR and Western blot for stemness markers

• Perform functional assays (neurosphere formation, proliferation)

• Validate findings in xenograft models using CD97 antibodies for IHC/IF

What controls should be included when evaluating CD97 antibody specificity for research applications?

Comprehensive control strategies are essential for rigorous CD97 antibody validation:

Positive controls:

• Cell lines with validated CD97 expression (HepG2, K-562, U-937, Jurkat, HL-60, and DC2.4)

• Recombinant human CD97 protein for antibody binding assays

• CD97-transfected cells versus empty vector controls

Negative controls:

• Isotype control antibodies (e.g., MAB0031 for flow cytometry applications)

• CD97 knockout or knockdown cells (CRISPR-Cas9 or siRNA treated)

• Competitive binding with excess unlabeled antibody

• Secondary antibody-only controls

Cross-reactivity assessments:

• Test against mouse CD97 if working with human samples (some antibodies show no cross-reactivity with mouse CD97)

• Evaluate potential cross-reactivity with other EGF-TM7 family members

Validation methods:

• Western blot confirmation of the expected 75-85 kDa molecular weight

• Peptide competition assays to confirm epitope specificity

• Multiple antibody validation (use at least two antibodies targeting different epitopes)

• Correlation of protein detection with mRNA expression data

How can CD97 antibodies be utilized to develop CAR T cell therapeutics targeting CD97 in cancer?

CD97 antibodies play a crucial role in developing CAR T cell therapies against CD97-expressing cancers:

Antibody-derived scFv generation:

• Generate anti-CD97 human antibodies using hybridoma technology

• Characterize and sequence the extracellular single-chain variable fragment (scFv) of the antibody

• Optimize the scFv for CAR construction by modifying linker regions and framework areas

CAR construct design methodology:

• Clone the CD97-specific scFv sequence into a second-generation CAR construct

• Incorporate co-stimulatory domains (4-1BB) and activation domains (CD3ζ)

• Include reporter genes (GFP) to monitor transduction efficiency

• Validate construct expression in packaging cell lines

Functional validation protocol:

• Transduce T cells (preferably Th9 cells based on recent findings) with the CD97-CAR construct

• Confirm CAR expression by flow cytometry

• Assess cytotoxicity against CD97+ target cells at various effector-to-target ratios

• Measure cytokine production (especially IL-9 for Th9 cells)

• Evaluate CAR T cell persistence and expansion capacity

• Test efficacy in xenograft models and monitor survival rates

Critical considerations:

• Antibody affinity affects CAR T cell function (too high or too low affinity can reduce efficacy)

• Epitope location on CD97 influences accessibility for CAR recognition

• Testing multiple antibody-derived scFvs may be necessary to identify optimal candidates

What is known about CD97's molecular structure and how does this inform antibody selection?

CD97's complex molecular structure has important implications for antibody selection:

Structural characteristics:

• CD97 is a dimeric glycoprotein with a 75-90 kDa intracellular domain and a 28 kDa extracellular domain

• It belongs to the seven-transmembrane subfamily of the class B G protein-coupled receptor (GPCR) group

• The protein contains epidermal growth factor (EGF)-like domains in its extracellular region

Antibody selection considerations:

• Antibodies targeting different epitopes may yield varied results based on:

  • Accessibility of epitopes in native versus denatured conditions

  • Glycosylation status affecting epitope recognition

  • Splice variant expression in different tissues

Observable molecular weights:

• Western blot typically detects CD97 at 75-85 kDa

• The calculated molecular weight based on amino acid sequence is 79 kDa (722 amino acids)

• Variations in observed weight may reflect post-translational modifications or isoforms

Research applications based on structure:

• Native conformation antibodies are best for flow cytometry and IF applications

• Denaturation-resistant epitope antibodies work better for Western blot

• Multiple antibodies may be needed to capture all biologically relevant forms of CD97

What signaling pathways does CD97 regulate and how can antibodies help investigate these mechanisms?

CD97 regulates multiple signaling pathways that can be investigated using specific antibody approaches:

CD97-mTORC2-AKT signaling axis:

• Recent research demonstrates CD97 activates mTORC2, leading to AKT S473 phosphorylation

• This activation enhances expression of downstream genes including ARHGAP1, BZW1, and BZW2

Methodological approach to investigate signaling:

• Use CD97 antibodies to identify high/low expressing populations by flow cytometry or IF

• Perform CD97 silencing or neutralization experiments

• Assess changes in downstream pathway components by Western blot:

  • Phosphorylated AKT at S473

  • mTORC2 complex components

  • ARHGAP1, BZW1, and BZW2 expression levels

• Validate findings using pathway inhibitors (e.g., mTORC2 inhibitor JR-AB2-011)

• Correlate pathway activation with functional outcomes (self-renewal, proliferation, tumor progression)

Additional signaling connections:

• CD97 plays roles in cell adhesion mechanisms that can be studied using adhesion assays with CD97 antibody neutralization

• CD97-mediated cellular interactions can be quantified by antibody blocking experiments

How does CD97 expression vary across different cell types and disease states?

CD97 expression patterns vary significantly and can be characterized using appropriate antibody techniques:

Normal tissue expression:

• CD97 is predominantly expressed on:

  • T-cells (high expression)

  • Monocytes, macrophages, dendritic cells

  • Granulocytes

  • Smooth muscle cells

• B cells typically show minimal CD97 expression

• Flow cytometry analysis of whole blood reveals distinct CD97+ populations

Cancer-associated expression:

• Glioblastoma stem cells (GSCs) show uniform and specific expression of CD97

• CD97^high GSCs exhibit:

  • Increased stemness marker expression (CD133, Nestin, CD44)

  • Enhanced proliferation capacity

  • Greater self-renewal potential

  • More aggressive tumor formation in vivo

Expression analysis methods:

• Flow cytometry for quantitative single-cell analysis of surface CD97

• IHC for spatial distribution in tissue contexts (validated in tonsillitis and lymphoma tissues)

• Western blot for total protein expression levels

• qPCR for mRNA expression correlations

• Single-cell transcriptomics to identify CD97 expression in rare populations

Clinical correlations:

• High CD97 expression correlates with adverse outcomes in glioblastoma patients

• Expression patterns can be analyzed in relation to patient survival data

What are common technical challenges when detecting CD97 in different experimental systems?

Researchers may encounter several challenges when working with CD97 antibodies:

Western blot challenges:

• Problem: Multiple bands or unexpected molecular weights
  Solution: Optimize lysis conditions to preserve protein integrity; use fresh samples with protease inhibitors; consider isoforms/splice variants

• Problem: Weak signal detection
  Solution: Increase antibody concentration; extend incubation time; enhance blocking to reduce background; use more sensitive detection systems

Flow cytometry challenges:

• Problem: Low separation between positive and negative populations
  Solution: Optimize antibody concentration; use fluorophores with higher signal-to-noise ratio; improve compensation settings

• Problem: Non-specific binding
  Solution: Include proper blocking steps; use isotype controls (e.g., MAB0031) ; optimize wash steps

IHC/IF challenges:

• Problem: High background staining
  Solution: Optimize blocking; increase antibody dilution; use antigen retrieval with TE buffer pH 9.0 for better results

• Problem: Weak or variable staining
  Solution: Test different fixation methods; optimize antigen retrieval protocols; consider citrate buffer pH 6.0 as an alternative

General troubleshooting approach:

• Validate antibody performance using known positive controls (HepG2, K-562, U-937, Jurkat cells)

• Test multiple antibody dilutions systematically

• Optimize protocol steps specifically for CD97 detection

• Include appropriate negative controls

How can researchers effectively validate CD97 antibodies for novel applications?

Rigorous validation ensures reliable results when expanding CD97 antibody use to new applications:

Cross-application validation protocol:

• Begin with established applications (e.g., if an antibody works for WB, test it in IF)

• Use cell lines with confirmed CD97 expression as positive controls

• Include relevant negative controls (CD97-negative cells or tissues)

• Test antibody performance across a concentration gradient

• Compare results with alternative antibodies targeting different CD97 epitopes

New cell line/tissue validation:

• Correlate protein detection with mRNA expression

• Compare staining patterns with published literature

• Validate specificity using genetic knockdown approaches

• Confirm expected subcellular localization

Novel application consideration table:

Functional validation:

• For neutralizing applications, establish dose-response curves in adhesion assays

• Calculate ND50 values (typically 0.5-2.5 μg/mL for some CD97 antibodies)

• Confirm observed effects with orthogonal approaches

What are the best practices for preserving CD97 antibody activity during storage and experimental use?

Proper handling ensures optimal CD97 antibody performance and reproducible results:

Storage conditions:

• Store antibodies at -20°C for long-term stability

• For products containing 0.02% sodium azide and 50% glycerol (pH 7.3), aliquoting is unnecessary for -20°C storage

• Some formulations containing 0.1% BSA should be stored in small (20μl) aliquots

• Most CD97 antibodies remain stable for one year after shipment when properly stored

Working solution preparation:

• Thaw aliquots completely before use but minimize time at room temperature

• Mix gently by inversion rather than vortexing to prevent antibody denaturation

• Centrifuge briefly after thawing to collect all liquid

• Prepare fresh dilutions for each experiment

Experimental handling:

• Avoid repeated freeze-thaw cycles which can reduce antibody activity

• Keep antibodies on ice during experiment preparation

• When diluting, use recommended buffers (often PBS with carrier proteins)

• For flow cytometry, maintain cold temperatures throughout staining process

Long-term considerations:

• Document lot numbers and performance characteristics

• Include positive controls in each experiment to monitor antibody performance over time

• Consider stability-enhanced formulations for applications requiring longer incubation periods

How can CD97 antibodies be utilized in single-cell analysis techniques?

CD97 antibodies can enhance single-cell analysis through various cutting-edge applications:

Single-cell protein profiling:

• CD97 antibodies can be incorporated into mass cytometry (CyTOF) panels to correlate CD97 expression with dozens of other markers

• For multi-parameter flow cytometry, CD97 antibody conjugates can be combined with stemness markers (CD133, Nestin) and functional markers

Spatial transcriptomics integration:

• CD97 antibodies can be used in immunofluorescence coupled with in situ RNA detection

• This allows correlation between CD97 protein expression and transcriptional profiles at single-cell resolution

Methodological approach:

• Optimize CD97 antibody concentration for minimal background in single-cell applications

• Validate specificity using isotype controls and CD97-negative populations

• Develop compatible multiplexing protocols that maintain CD97 epitope integrity

• Integrate data with computational analysis pipelines to identify CD97-associated cell states

Research applications:

• Identification of rare CD97+ subpopulations within heterogeneous tumors

• Tracking CD97 expression changes during cellular differentiation or disease progression

• Correlation of CD97 expression with functional cellular states in complex tissues

What is the significance of CD97 in cancer therapeutic resistance and how can antibodies help study this phenomenon?

CD97's role in therapeutic resistance represents an important research area where antibodies provide critical insights:

CD97 and therapy resistance mechanisms:

• CD97^high populations in glioblastoma show enhanced tumorigenicity and potentially treatment resistance

• CD97 activates mTORC2/AKT signaling, a pathway implicated in multiple resistance mechanisms

• The downstream targets (ARHGAP1, BZW1, BZW2) may mediate resistance phenotypes

Research methodology using CD97 antibodies:

• Isolate CD97^high and CD97^low populations from patient samples using flow cytometry

• Compare therapy response profiles between populations

• Perform time-course analyses of CD97 expression during treatment

• Assess CD97 levels in recurrent tumors versus primary tumors

• Develop combination approaches using CD97-targeting alongside standard therapies

Therapeutic resistance assessment:

• Use CD97 antibodies to monitor expression changes following treatment

• Correlate CD97 levels with clinical outcomes and therapy response

• Develop predictive models based on CD97 expression patterns

Combination therapy strategies:

• Study CD97-targeting CAR T cell therapy in combination with mTORC2 inhibitors

• Evaluate resistance mechanisms to CD97-targeted therapies

• Monitor CD97 expression changes during treatment as potential resistance indicators